Europe

This archive covers progress stories and milestones from across Europe, spanning health, climate policy, social equity, and scientific research. From small-nation experiments to E.U.-wide initiatives, these reports highlight what is working and why.

Cannabis being weighed, for article on legal cannabis dispensary, for article on Germany cannabis legalization

Germany to become second E.U. nation to legalize recreational cannabis

By / / Good News For Humankind

Recreational cannabis legalization in Germany would mark a significant shift for Europe’s largest economy — moving the country away from a prohibition model that its own health minister says has shown no clear results. The proposal would allow licensed shops and pharmacies to sell cannabis to adults, with age-based limits on potency designed to protect younger users. Because Germany sits at the heart of the E.U., its approach could reshape how other member states think about drug policy far more than smaller precedents have. This is what evidence-based reform looks like in practice.

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment, for article on psilocybin therapy

The world’s first Phase 3 psilocybin clinical trial is about to commence

By / / Good News For Humankind

Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.